“Rheumatoid Arthritis Treatment: DMARDs, Biologics, and Regenerative Approaches”

Why Early Treatment Changes Everything

If there is one thing rheumatologists agree on, it is this: time matters. Rheumatoid arthritis is not a disease you can afford to wait and watch. There is a critical “window of opportunity” in the first three to six months after symptoms begin, during which aggressive treatment can dramatically alter the long-term course of the disease [1].

Left untreated, RA causes progressive erosion of cartilage and bone. Once that structural damage occurs, it is irreversible. Joint replacement surgery becomes a real possibility. But patients who start disease-modifying therapy early have significantly better outcomes at five, ten, and twenty years compared to those who delay, even by a few months [2].

This is why rheumatologists now follow a “treat-to-target” strategy: set a specific goal (usually low disease activity or remission as measured by validated scoring tools), treat aggressively toward that goal, and adjust therapy every three months until you get there.

Understanding the Treat-to-Target Approach

Treat-to-target sounds straightforward, but it represents a major shift from how RA was managed a generation ago. The approach borrows from endocrinology and cardiology, where treating to specific numbers (blood sugar, blood pressure) is standard practice.

In RA, the most commonly used scoring tool is the DAS28 (Disease Activity Score using 28 joints). It combines tender joint count, swollen joint count, an inflammatory blood marker (CRP or ESR), and a patient-reported global assessment into a single number [3].

• DAS28 > 5.1: High disease activity
• DAS28 3.2 to 5.1: Moderate disease activity
• DAS28 2.6 to 3.2: Low disease activity
• DAS28 < 2.6: Remission

The target for most patients is either remission or low disease activity. If you are not at target after three months on a given therapy, your rheumatologist should be talking to you about adjusting the plan. If your doctor is not measuring disease activity at every visit, ask about it.

Conventional DMARDs: Starting with Methotrexate

Disease-modifying anti-rheumatic drugs (DMARDs) are the backbone of RA treatment. Unlike painkillers, which mask symptoms, DMARDs actually slow or stop the immune-mediated destruction of joints.

Methotrexate

Methotrexate has been the anchor drug in RA treatment for over thirty years, and for good reason. It works for roughly 40-60% of patients as monotherapy, it is inexpensive, it has decades of long-term safety data, and it enhances the effectiveness of nearly every biologic agent it is combined with [4].

Methotrexate is taken once weekly (not daily) at doses typically between 15-25 mg. Folic acid supplementation is taken on the other days to reduce side effects like nausea, mouth sores, and liver enzyme elevation. Most side effects are manageable, and the drug is far better tolerated than its reputation suggests. Regular blood monitoring (CBC and liver function) is required, typically every eight to twelve weeks once on a stable dose.

Other Conventional DMARDs

When methotrexate alone is insufficient or not tolerated, other conventional DMARDs may be added or substituted:

• Sulfasalazine: Often used in combination with methotrexate. Moderately effective. Can cause GI upset and requires monitoring for blood count changes.
• Leflunomide: Similar efficacy to methotrexate. Cannot be combined with methotrexate due to overlapping liver toxicity. Useful as an alternative for patients who cannot tolerate methotrexate.
• Hydroxychloroquine: The mildest DMARD. Sometimes used in combination (“triple therapy” with methotrexate and sulfasalazine) but rarely effective enough as monotherapy for moderate to severe RA.

Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) has been shown in head-to-head trials to perform comparably to methotrexate plus a TNF inhibitor for many patients, making it a reasonable first escalation step, especially where cost is a concern [5].

Biologic DMARDs: When Conventional Therapy Falls Short

Biologics are genetically engineered proteins that target specific components of the immune system driving RA inflammation. They represent one of the great therapeutic advances of the past twenty-five years.

TNF Inhibitors

Tumor necrosis factor (TNF) is a key inflammatory cytokine in RA. TNF inhibitors were the first biologics developed for RA and remain the most commonly used class:

• Adalimumab (Humira): Subcutaneous injection every two weeks.
• Etanercept (Enbrel): Subcutaneous injection weekly.
• Infliximab (Remicade): IV infusion every 6-8 weeks.
• Certolizumab (Cimzia): Subcutaneous injection every two weeks (safe in pregnancy due to lack of placental transfer).
• Golimumab (Simponi): Subcutaneous injection monthly.

TNF inhibitors, when added to methotrexate, produce significant clinical improvement in 60-70% of patients. They also slow radiographic progression of joint damage [6]. Biosimilars are now available for adalimumab, etanercept, and infliximab at lower cost.

Non-TNF Biologics

For patients who do not respond to TNF inhibitors, or who have contraindications, several other biologic targets are available:

• Tocilizumab (Actemra): Blocks the IL-6 receptor. Particularly effective for systemic symptoms like fatigue and anemia. Can be used as monotherapy (without methotrexate), unlike most biologics [7].
• Abatacept (Orencia): Blocks T-cell co-stimulation via CTLA-4. Good safety profile. May be preferred in patients with a history of infections.
• Rituximab (Rituxan): Depletes B cells. Typically reserved for patients who have failed TNF inhibitors. Given as two IV infusions separated by two weeks, repeated every six months as needed.
• Sarilumab (Kevzara): Another IL-6 receptor blocker, similar to tocilizumab.

Choosing Between Biologics

There is no single “best” biologic. The choice depends on patient factors (comorbidities, infection history, pregnancy plans), route preference (injection vs. infusion), insurance coverage, and whether the patient can tolerate background methotrexate. If a first TNF inhibitor fails, switching to a different mechanism of action is generally preferred over trying a second TNF inhibitor, though both approaches are supported by evidence [8].

JAK Inhibitors: The Oral Alternative

Janus kinase (JAK) inhibitors are small molecules (not biologics) that can be taken as daily pills. They block intracellular signaling pathways downstream of multiple inflammatory cytokines, giving them a broad anti-inflammatory effect.

Three JAK inhibitors are currently approved for RA:

• Tofacitinib (Xeljanz): The first approved. Twice-daily dosing.
• Baricitinib (Olumiant): Once-daily dosing.
• Upadacitinib (Rinvoq): Once-daily dosing. Has shown superiority to adalimumab in head-to-head trials [9].

JAK inhibitors offer comparable efficacy to biologics, and some patients prefer the convenience of an oral medication over injections. However, safety signals have emerged. The ORAL Surveillance trial of tofacitinib found increased rates of major cardiovascular events and malignancies compared to TNF inhibitors in patients over 50 with cardiovascular risk factors [10]. As a result, current guidelines recommend trying a biologic before a JAK inhibitor in most cases, and using JAK inhibitors with caution in patients with cardiovascular risk.

Regenerative Approaches

While conventional and biologic DMARDs focus on suppressing the immune attack, regenerative medicine asks a different question: can we repair or rebuild what has already been damaged?

Platelet-Rich Plasma (PRP) for RA Joints

PRP involves concentrating growth factors from a patient’s own blood and injecting them into affected joints. In osteoarthritis, PRP has a growing evidence base. For RA, the data is more limited, but early studies show potential.

A 2020 randomized trial comparing PRP injection to corticosteroid injection in RA knee joints found that PRP provided longer-lasting pain relief and better functional outcomes at six months, though both groups improved initially [11]. The anti-inflammatory properties of certain growth factors in PRP may provide benefit beyond simple joint lubrication, though larger trials are needed before PRP becomes a standard recommendation in RA.

Mesenchymal Stem Cell (MSC) Therapy

MSCs have immunomodulatory properties that make them theoretically attractive for autoimmune conditions. They suppress T-cell proliferation, promote regulatory T cells, and release anti-inflammatory cytokines. Several Phase I/II trials of MSC infusions in RA have shown safety and preliminary signals of efficacy, with some patients achieving reduced disease activity scores [12].

However, this work is still early-stage. Optimal cell source (bone marrow, adipose, umbilical cord), dosing, route of delivery, and long-term safety all remain open questions. MSC therapy for RA should currently be considered experimental.

Low-Dose Naltrexone (LDN) as an Adjunct

Low-dose naltrexone (typically 1.5 to 4.5 mg nightly) has attracted significant patient interest for autoimmune conditions, including RA. The proposed mechanism involves transient blockade of opioid receptors, leading to upregulation of endogenous endorphins and enkephalins, which in turn modulate immune function and reduce inflammation via toll-like receptor 4 (TLR4) pathways [13].

A 2022 retrospective study found that RA patients who added LDN to their existing regimen showed improvements in pain scores and inflammatory markers, with minimal side effects [14]. Prospective randomized trials are underway but not yet completed. LDN is inexpensive and well-tolerated (the most common side effects are vivid dreams and mild insomnia during the first week), making it an appealing option for patients looking to supplement their existing therapy.

LDN should not be used as a replacement for DMARDs. It is best considered an adjunct, particularly for patients who have residual symptoms despite optimized conventional therapy.

When to Start Treatment (and What Happens If You Wait)

The evidence is clear: starting DMARD therapy within three months of symptom onset produces better outcomes than starting at six months, which produces better outcomes than starting at twelve months [15]. Every month of uncontrolled inflammation is a month of potential joint damage that cannot be undone.

If you have joint swelling, morning stiffness lasting more than thirty minutes, and elevated inflammatory markers, do not wait for a definitive diagnosis to begin treatment. Current guidelines support starting methotrexate on clinical suspicion of RA, even before all classification criteria are met.

Putting It All Together: A Treatment Ladder

The typical treatment progression for RA looks something like this:

1. Step 1: Methotrexate (with folic acid), titrated to an effective dose. Short course of low-dose prednisone as a “bridge” while waiting for methotrexate to take full effect (6-12 weeks).
2. Step 2: If target not reached at three months: add a second conventional DMARD (triple therapy) or add a biologic (usually a TNF inhibitor).
3. Step 3: If target still not reached: switch biologic mechanism (e.g., from TNF inhibitor to IL-6 blocker or abatacept).
4. Step 4: Consider JAK inhibitors if biologics have failed or are not tolerated.
5. Step 5: Adjunctive therapies (LDN, PRP for specific joints, occupational therapy, joint-protective strategies).

At every step, the goal is the same: get to low disease activity or remission and stay there. RA is a marathon, not a sprint. But with today’s therapies, sustained remission is achievable for a large and growing percentage of patients.

References

1. Combe B, et al. “EULAR recommendations for the management of early arthritis.” Ann Rheum Dis. 2017;76(6):948-959. doi:10.1136/annrheumdis-2016-210602
2. Finckh A, et al. “Early treatment of rheumatoid arthritis: the window of opportunity.” Arthritis Rheum. 2006;54(12):3863-3870. doi:10.1002/art.22263
3. Prevoo ML, et al. “Modified disease activity scores that include twenty-eight-joint counts.” Arthritis Rheum. 1995;38(1):44-48. doi:10.1002/art.1780380107
4. Weinblatt ME. “Methotrexate in rheumatoid arthritis: a quarter century of development.” Trans Am Clin Climatol Assoc. 2013;124:16-25. PMID: 23874006
5. O’Dell JR, et al. “Therapies for active rheumatoid arthritis after methotrexate failure.” N Engl J Med. 2013;369(4):307-318. doi:10.1056/NEJMoa1303006
6. Lipsky PE, et al. “Infliximab and methotrexate in the treatment of rheumatoid arthritis.” N Engl J Med. 2000;343(22):1594-1602. doi:10.1056/NEJM200011303432202
7. Burmester GR, et al. “Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.” Ann Rheum Dis. 2016;75(6):1081-1091. doi:10.1136/annrheumdis-2015-207628
8. Smolen JS, et al. “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.” Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356
9. Fleischmann R, et al. “Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis: SELECT-COMPARE.” Arthritis Rheumatol. 2019;71(11):1788-1800. doi:10.1002/art.41032
10. Ytterberg SR, et al. “Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.” N Engl J Med. 2022;386(4):316-326. doi:10.1056/NEJMoa2109927
11. Badsha H, et al. “Platelet-rich plasma versus corticosteroid injection for rheumatoid arthritis of the knee: a randomized controlled trial.” Clin Rheumatol. 2020;39(12):3603-3611. doi:10.1007/s10067-020-05138-1
12. Álvaro-Gracia JM, et al. “Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.” Ann Rheum Dis. 2017;76(1):196-202. doi:10.1136/annrheumdis-2015-208918
13. Younger J, et al. “Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.” Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734
14. Raknes G, Småbrekke L. “Low-dose naltrexone and RA: a retrospective study.” Scand J Rheumatol. 2022;51(3):235-241. doi:10.1080/03009742.2021.1998612
15. van der Linden MPM, et al. “Long-term impact of delay in assessment of patients with early arthritis.” Arthritis Rheum. 2010;62(12):3537-3546. doi:10.1002/art.27692

Related Reading

• Rheumatoid Arthritis: A Complete Guide
• Rheumatoid Arthritis Symptoms
• Rheumatoid Arthritis Diet
• Osteoarthritis vs. Rheumatoid Arthritis